Literature DB >> 10723577

Conditioning regimens for the treatment of experimental arthritis with autologous bone marrow transplantation.

D W van Bekkum1.   

Abstract

Adjuvant induced arthritis (AA) in Buffalo rats is a chronic progressive disease that responds very well to treatment with myeloablation and rescue with autologous BM. These previous results were obtained by conditioning with a lethal single dose of TBI. In the present study various other conditioning regimens were compared with single dose TBI. Fractionated TBI using adjusted total dose was equally effective. CY and BU when used as single agents at the highest tolerated dose were less effective. Combinations of CY (2 x 60 mg/kg) with lower dose (4 Gy) TBI and of BU with CY were as beneficial as high-dose TBI. These results indicate that a very intense reduction of T lymphocytes, in the order of 3-4 log, is required for obtaining the highest rate of long-lasting complete remissions. A similar conclusion was reached from our studies of various conditioning regimens in rats suffering from experimental allergic encephalitis (EAE). If extrapolated to the clinic, such a degree of T lymphocyte eradication poses upper limits to the number of T lymphocytes that can be safely reintroduced with the autograft. The exact limits cannot be derived from these experiments because the addition of autologous T lymphocytes to the graft yielded different results in the two models of autoimmune disease (AID).

Entities:  

Mesh:

Year:  2000        PMID: 10723577     DOI: 10.1038/sj.bmt.1702153

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  15 in total

Review 1.  Immune ablation and stem-cell therapy in autoimmune disease. Experimental basis for autologous stem-cell transplantation.

Authors:  D W Bekkum
Journal:  Arthritis Res       Date:  2000-06-02

2.  High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes.

Authors:  Peter A McSweeney; Richard A Nash; Keith M Sullivan; Jan Storek; Leslie J Crofford; Roger Dansey; Maureen D Mayes; Kevin T McDonagh; J Lee Nelson; Theodore A Gooley; Leona A Holmberg; C S Chen; Mark H Wener; Katherine Ryan; Julie Sunderhaus; Ken Russell; John Rambharose; Rainer Storb; Daniel E Furst
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

3.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.

Authors:  Richard A Nash; Peter A McSweeney; Leslie J Crofford; Muneer Abidi; Chien-Shing Chen; J David Godwin; Theodore A Gooley; Leona Holmberg; Gretchen Henstorf; C Fred LeMaistre; Maureen D Mayes; Kevin T McDonagh; Bernadette McLaughlin; Jerry A Molitor; J Lee Nelson; Howard Shulman; Rainer Storb; Federico Viganego; Mark H Wener; James R Seibold; Keith M Sullivan; Daniel E Furst
Journal:  Blood       Date:  2007-04-23       Impact factor: 22.113

Review 4.  Adult stem cell therapy for autoimmune disease.

Authors:  Eun Wha Choi
Journal:  Int J Stem Cells       Date:  2009-05       Impact factor: 2.500

5.  Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

Authors:  Keith M Sullivan; Ellen A Goldmuntz; Lynette Keyes-Elstein; Peter A McSweeney; Ashley Pinckney; Beverly Welch; Maureen D Mayes; Richard A Nash; Leslie J Crofford; Barry Eggleston; Sharon Castina; Linda M Griffith; Julia S Goldstein; Dennis Wallace; Oana Craciunescu; Dinesh Khanna; Rodney J Folz; Jonathan Goldin; E William St Clair; James R Seibold; Kristine Phillips; Shin Mineishi; Robert W Simms; Karen Ballen; Mark H Wener; George E Georges; Shelly Heimfeld; Chitra Hosing; Stephen Forman; Suzanne Kafaja; Richard M Silver; Leroy Griffing; Jan Storek; Sharon LeClercq; Richard Brasington; Mary E Csuka; Christopher Bredeson; Carolyn Keever-Taylor; Robyn T Domsic; M Bashar Kahaleh; Thomas Medsger; Daniel E Furst
Journal:  N Engl J Med       Date:  2018-01-04       Impact factor: 91.245

Review 6.  Stem cell transplantation in experimental models of autoimmune disease.

Authors:  D W van Bekkum
Journal:  J Clin Immunol       Date:  2000-01       Impact factor: 8.317

7.  Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration.

Authors:  R J Verburg; R Flierman; J K Sont; F Ponchel; L van Dreunen; E W Levarht; M M Welling; R E M Toes; J D Isaacs; J M van Laar
Journal:  Ann Rheum Dis       Date:  2005-04-13       Impact factor: 19.103

Review 8.  Hematopoietic stem cell transplantation for non-malignant gastrointestinal diseases.

Authors:  Abdulbaqi Al-toma; Petula Nijeboer; Gerd Bouma; Otto Visser; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

9.  High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.

Authors:  Richard A Nash; James D Bowen; Peter A McSweeney; Steven Z Pavletic; Kenneth R Maravilla; Man-soo Park; Jan Storek; Keith M Sullivan; Jinan Al-Omaishi; John R Corboy; John DiPersio; George E Georges; Theodore A Gooley; Leona A Holmberg; C Fred LeMaistre; Kate Ryan; Harry Openshaw; Julie Sunderhaus; Rainer Storb; Joseph Zunt; George H Kraft
Journal:  Blood       Date:  2003-05-22       Impact factor: 22.113

Review 10.  Application of stem cell transplantation in autoimmune diseases.

Authors:  Sue-Ann Ng; Keith M Sullivan
Journal:  Curr Opin Hematol       Date:  2019-11       Impact factor: 3.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.